Solubility varies far more across this subcategory than within the incretins. A compound that needs a specific diluent or a specific pH is not being difficult; it has a solubility profile and the supplier should state it. A single observation, in a thread that deserves better than single observations.
Posting this under the heading it deserves: Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Everything below is what sits behind that.
Melanocortin agonists, from the point of view of someone who has read the documentation and is still stuck.
Saying which parts I have understood so that nobody wastes time re-explaining them, and where exactly the understanding stops.
Everything in the opening post holds. The case it does not cover is the one I have.
Melanotan II is a non-selective melanocortin agonist, which is why its effects are not confined to pigmentation. The non-selectivity is the mechanism and not a side issue.
I checked the source rather than the summary, and they differ.
Melanocortin agonists is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
The reason Melanocortin agonists keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.
PT-141 was developed from the same family with a different receptor profile, and it has a considerably better documented human evidence base than most compounds discussed in this subcategory.
Answering the question post #2 raises rather than the one it answers.
Two people in this thread mean different things by Melanocortin agonists and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.
Solubility varies far more across this subcategory than within the incretins. A compound that needs a specific diluent or a specific pH is not being difficult; it has a solubility profile and the supplier should state it.
A single observation, in a thread that deserves better than single observations.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
I would put this at better than even and not much better.
Counterpoint on Melanocortin agonists, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
Post #9 put the caveat in the right place and I want to underline it.
On analysis: unusual or modified sequences are exactly where a default reversed-phase method is least likely to be appropriate. A supplier that runs everything on one gradient will produce a flattering result for something.
I have said this before in a thread nobody could find, so it is worth repeating.
Fine by me. I had wanted a stronger conclusion and there is not one available.
Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.
Posted with less confidence than the sentence structure implies.
Where I part company with post #15, and it is a narrow parting.
A note on how Melanocortin agonists gets discussed rather than on Melanocortin agonists itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.
Noted, and thank you for writing it out rather than summarising it.
Adding the measurement that post #17 says would settle it.
The honest summary for most of this subcategory: a plausible mechanism, animal data, and first-hand accounts. Saying so is more useful than assembling the accounts into something that reads like evidence.
I would treat the number as indicative rather than as a measurement.
Picking up post #21: that is the part I would want checked first.
Taking Melanocortin agonists seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.
AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.
Marking my uncertainty on Melanocortin agonists explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.
If someone has run Melanocortin agonists properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
This follows post #26 rather than contradicting it.
Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning.
Not the whole picture, but the part of it I can speak to.
Worth separating two things that post #24 runs together.
A methods point on Melanocortin agonists rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method.
Solubility varies far more across this subcategory than within the incretins. A compound that needs a specific diluent or a specific pH is not being difficult; it has a solubility profile and the supplier should state it.